142 related articles for article (PubMed ID: 22728984)
1. [In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].
Kusumoto K
Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):236-40. PubMed ID: 22728984
[No Abstract] [Full Text] [Related]
2. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
3. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
Barrios V; Escobar C
Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
[TBL] [Abstract][Full Text] [Related]
4. [Azilsartan: a new angiotensin receptor blocker].
Rakugi H; Enya K
Nihon Rinsho; 2012 Sep; 70(9):1615-20. PubMed ID: 23012812
[TBL] [Abstract][Full Text] [Related]
5. Azilsartan medoxomil for the treatment of hypertension.
Vasiliou S
Drugs Today (Barc); 2011 Sep; 47(9):647-51. PubMed ID: 21971539
[TBL] [Abstract][Full Text] [Related]
6. [Azilsartan: Whether it Will Expand Treatment Options for Arterial Hypertension?].
Nedogoda SV
Kardiologiia; 2015; 55(4):97-100. PubMed ID: 26502510
[No Abstract] [Full Text] [Related]
7. [Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity].
Vasyuk YA; Shupenina EY; Nesvetov VV; Nesterova EA; Golubkova EI
Kardiologiia; 2016 Dec; 56(11):108-112. PubMed ID: 28290827
[TBL] [Abstract][Full Text] [Related]
8. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
9. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
10. Critical evaluation of the efficacy and tolerability of azilsartan.
De Caterina AR; Harper AR; Cuculi F
Vasc Health Risk Manag; 2012; 8():299-305. PubMed ID: 22661897
[TBL] [Abstract][Full Text] [Related]
11. Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension.
Kamada T; Hayashi M; Fujiwara W; Yoshikawa D; Mukaide D; Sugishita Y; Yoshinaga M; Itoh T; Yokoi H; Ishii J; Watanabe E; Ozaki Y; Izawa H
Drug Chem Toxicol; 2017 Jan; 40(1):110-114. PubMed ID: 27424785
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
Kurtz TW; Kajiya T
Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Shuster JE; Bleske BE; Dorsch MP
Vasc Health Risk Manag; 2012; 8():381-7. PubMed ID: 22745562
[TBL] [Abstract][Full Text] [Related]
14. Azilsartan: Novel Angiotensin Receptor Blocker.
Dargad RR; Parekh JD; Dargad RR; Kukrety S
J Assoc Physicians India; 2016 Mar; 64(3):96-98. PubMed ID: 27731574
[TBL] [Abstract][Full Text] [Related]
15. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
16. Azilsartan attenuates cardiac damage caused by high salt intake through the downregulation of the cardiac (pro)renin receptor and its downstream signals in spontaneously hypertensive rats.
Komaki H; Iwasa M; Hayakawa Y; Okamoto C; Minatoguchi S; Yamada Y; Kanamori H; Kawasaki M; Nishigaki K; Minatoguchi S
Hypertens Res; 2018 Nov; 41(11):886-896. PubMed ID: 30209283
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system blockade and pleiotropic cardiovascular effects: the novel angiotensin receptor blocker azilsartan.
Adiyaman A; Adiyaman I; Elvan A
Hypertens Res; 2014 May; 37(5):395-7. PubMed ID: 24572911
[No Abstract] [Full Text] [Related]
18. Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan.
Iwanami J; Mogi M; Tsukuda K; Wang XL; Nakaoka H; Ohshima K; Chisaka T; Bai HY; Kanno H; Min LJ; Horiuchi M
Hypertens Res; 2014 Jul; 37(7):616-20. PubMed ID: 24599018
[TBL] [Abstract][Full Text] [Related]
19. New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.
Hussar DA; Shah A
J Am Pharm Assoc (2003); 2011; 51(3):444-7. PubMed ID: 21555300
[No Abstract] [Full Text] [Related]
20. Antihypertensive effect of azilsartan versus olmesartan in patients with essential hypertension: a meta-analysis.
Zhao D; Liu H; Dong P
Ir J Med Sci; 2019 May; 188(2):481-488. PubMed ID: 29971568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
